# ClinicalTrials.gov record NCT02020629

> PeptideScanner retained ClinicalTrials.gov record NCT02020629 at 2026-07-30T21:39:57.678Z. Its registry update date was 2015-12-15, and PeptideScanner's reviewed identity mapping was lixisenatide.

- Evidence object: `story:clinicaltrials-gov-nct02020629-lixisenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-12-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02020629-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02020629-lixisenatide-v1.json
- Content SHA-256: `86848b6f9611f1d62dfe75521b165051faa5312305f1ac74e949120eea2a9d49`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT02020629 ([`ctg-observation-nct02020629-2015-12-15-1826448515fe`](#source-ctg-observation-nct02020629-2015-12-15-1826448515fe))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02020629 at 2026-07-30T21:39:57.678Z. Its registry update date was 2015-12-15, and PeptideScanner's reviewed identity mapping was lixisenatide. ([`ctg-observation-nct02020629-2015-12-15-1826448515fe`](#source-ctg-observation-nct02020629-2015-12-15-1826448515fe))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02020629 at 2026-07-30T21:39:57.678Z. Its registry update date was 2015-12-15, and PeptideScanner's reviewed identity mapping was lixisenatide. ([`ctg-observation-nct02020629-2015-12-15-1826448515fe`](#source-ctg-observation-nct02020629-2015-12-15-1826448515fe))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02020629-2015-12-15-1826448515fe`](#source-ctg-observation-nct02020629-2015-12-15-1826448515fe))

## Sources

<a id="source-ctg-observation-nct02020629-2015-12-15-1826448515fe"></a>
- **ClinicalTrials.gov record NCT02020629 · retained source version 2015-12-15:1826448515fe317ebd0379b42b81b9a6d0cb291144698164d932b2b91275325b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02020629) (`ctg-observation-nct02020629-2015-12-15-1826448515fe`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02020629." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02020629-lixisenatide-v1.json SHA-256: 86848b6f9611f1d62dfe75521b165051faa5312305f1ac74e949120eea2a9d49.